SWOG clinical trial number
SWOG-9024

A Pilot Study of Combined Modality Therapy in T3, 4; N0, M0 Adenocarcinoma of the Prostate, Phase II

Closed
Phase
Accrual
62%
Published
Abbreviated Title
A Pilot Study of Combined Modality Therapy in T3, 4; N0, M0 Adenocarcinoma of the Prostate, Phase II
Activated
08/01/1991
Closed
03/15/1995

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2006

Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group study 9024

GP Swanson;J Faulkner;SR Smalley;MJ Noble;RL Stephens;TJ O'Rourke;GR Weiss;DP Quick;IM Thompson, Jr;ED Crawford Journal of Urology 176:548-553

1997

Protracted venous infusion (PVI) 5-FU and radiation as definitive therapy for stage C prostate cancer - a Southwest Oncology Group phase II study.

S Smalley;D Lew;I Thompson;M Sarosdy;R Stephens;M Noble;B Kimler Proc of the American Society of Clinical Oncology 16:343a(#1228)

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase